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Abstract
Little is known of the role of human leucocyte antigen (HLA) alleles or non-HLA
alleles in determining resistance, susceptibility or the severity of acute viral
infections. Dengue fever (DF) and dengue haemorrhagic fever (DHF) are suitable
models for immunogenetic studies, yet only superficial efforts have been made to
study dengue disease to date. DF and DHF can be caused by both primary and
secondary infection by any of the four serotypes of the dengue virus. Differences in
host susceptibility to infectious disease and disease severity cannot be attributed
solely to the virus virulence. Variations in immune response, often associated with
polymorphism in the human genome, can now be detected. Data on the influence
of human genes in DF and DHF are discussed here in relation to (1) associations
between HLA polymorphism and dengue disease susceptibility or resistance, (2)
protective alleles influencing progression to severe disease, (3) alleles restricting
CD41 and CD81 T lymphocytes, and (4) non-HLA genetic factors that may
contribute to DHF evolution. Recent discoveries regarding genetic associations in
other viral infections may provide clues to understanding the development of end-
stage complications in dengue disease. The scanty positive data presented here
indicate a need for detailed genetic studies in different ethnic groups in different
countries during the acute phase of DF and DHF on a larger number of patients.
Introduction
Dengue produces a mild acute febrile illness, dengue fever
(DF), and a life-threatening severe illness, dengue haemor-
rhagic fever (DHF; Agarwal et al., 1999a). DHF has emerged
as the most important arbovirus disease in humans in the
last three decades. It has been estimated that about 50–100
million cases of DF occur every year, and about
250 000–500 000 cases of DHF (Rigau-Perez et al., 1998),
affecting a very large proportion of children (Halstead, 2002;
Chaturvedi & Shrivastava, 2004). The years 2001–2003
witnessed unprecedented global dengue epidemics, with a
large number of DHF cases (Chaturvedi & Shrivastava,
2004). DHF has been classified into four grades: the mildest
is grade I and the most severe is grade IV. The classical
features of DHF are increased capillary permeability without
morphological damage to the capillary endothelium, altered
number and functions of leucocytes, and increased haema-
tocrit and thrombocytopoenia (Halstead, 1993; Chaturvedi
et al., 1997). Extensive plasma leakage in various serous
cavities of the body in DHF grades III and IV may result in
profound shock, the dengue shock syndrome (DSS). The
risk factors for DHF are infestation with Aedes mosquito, a
hot and humid climate promoting mosquito breeding,
mosquito density, the presence of all four serotypes of the
dengue virus (DV) with secondary infection in the host,
poor-quality water storage facilities in people’s homes, a
high population density and large movement of people
towards urban areas. The sequence of infection with differ-
ent DV serotypes may be important, e.g. DV-1 then DV-2 or
DV-1 then DV-3 are capable of inducing DHF/DSS (re-
viewed by Chaturvedi & Shrivastava, 2004; Chaturvedi et al.,
2005). Antibody-dependent enhancement (ADE), a pheno-
menon first described by Halstead and colleagues (Halstead,
1970; Halstead et al., 1970) in which DV replication is
increased by immune sera (IgG), has been observed in vitro
for a large number of viruses. ADE via IgM and complement
C3 receptors has also been reported (Cardosa et al., 1983).
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Using a dynamic system model of co-circulating dengue
serotypes, Cummings et al. (2005) have shown that ADE
may provide a competitive advantage to those serotypes that
undergo enhancement compared with those that do not,
and that this advantage increases with increasing numbers
of co-circulating serotypes. Paradoxically, there are limits
to the selective advantage provided by increasing levels of
ADE, because greater levels of enhancement induce high-
amplitude oscillations in incidence of all DV infections,
threatening the persistence of both the enhanced and the
nonenhanced serotypes. These results suggest that enhance-
ment is most advantageous in settings where multiple
serotypes circulate and where a large host population is
available to support pathogen persistence during the deep
troughs of ADE-induced high-amplitude oscillations of
virus replication. Ferguson et al. (1999) have suggested
that enhancement may frequently generate complex and
persistent cyclical or chaotic epidemic behaviour. Further-
more, enhancement acts to permit the coexistence of all
strains where in its absence only one or a subset would
persist.
At present, there is no vaccine or specific therapy available
for DHF. Pre-existing heterotypic dengue antibody is a risk
factor for DHF, and therefore an effective vaccine will have
to be tetravalent and needs to prevent infection with all four
DV serotypes. Natural DV infection induces long-lasting
protective immunity only to the same serotype. A tetrava-
lent formulation that retains the immunogenicity of all four
serotypes has proven difficult to produce, requiring the use
of more complicated, multiple-dose immunization regi-
mens. A more significant obstacle is the current inability to
predict whether candidate DV vaccines will be at all effective
in preventing DHF. Studies of candidate vaccines have
analysed efficacy only in experimental animal models, none
of which faithfully reproduce the DHF syndrome seen in
humans. Therefore, selection of the most promising DV
vaccine candidates relies on comparing vaccine-induced
immune responses with a profile of protective immunity
developed from natural DV infections (reviewed by Chatur-
vedi et al., 2005). Appropriate symptomatic treatment has
been successful in reducing the mortality associated with
DHF (Chaturvedi & Shrivastava, 2004).
Emergence and re-emergence of DF and DHF continue to
be a global challenge. Evolution of the genetics of hosts,
pathogens and vectors has been phenomenal and the
extensive growth of genetic studies has greatly increased
our understanding of the transmission and pathogenicity of
infectious diseases. The profound influence of the host’s
genetic makeup on resistance to infections has been estab-
lished in numerous studies. It has been shown that suscept-
ibility to many infectious and parasitic diseases has a genetic
basis, and the molecular epidemiology and virulence of
pathogenic agents, as well as their resistance to drugs,
vaccines and antibiotics, are well known in certain condi-
tions (Abel & Dessein, 1998; McNicoll, 1998). The present
paper reviews the existing knowledge dealing with the host
genetics and its implication in the pathogenesis of severe
dengue disease. The discussion includes genetic association
with the clinical disease and the genetic restriction of cells
such as CD41 and CD81 lymphocytes and the dendritic
cells (DCs) that appear to play an important role in the
pathogenesis of DHF. Because of space constraints only
selected work has been cited.
Immune response to DV
Dengue virus has 10 viral proteins including the core (C)
and membrane (M) proteins, the envelope (E) glycoprotein
and seven non-structural (NS) proteins. Anti-E antibodies
inhibit DV binding to cells, neutralize viral infectivity in
vitro, show a variable degree of cross-reactivity among the
DV serotypes and protect mice from DV challenge on
passive transfer (Kaufman et al., 1987; Roehrig et al., 1998).
Envelope protein domain III (E-D3) is conserved between
different flaviviruses. E-D3 is immunogenic, is highly stable
and is the cell receptor binding domain recognized by
polyclonal and monoclonal antibodies. Thullier et al.
(2001) have suggested that the E (306–314) segment is
critical for the infectivity of all DV serotypes and that
murine monoclonal antibody 4E11 neutralizes DV of all
serotypes by binding to the 296–400 segment of the major
DV E glycoprotein. The uptake of DV into monocytic cell
lines and primary human monocytes in vitro is enhanced
through binding of antibody to virus at non-neutralizing
epitopes with cell-surface Ig receptors or at concentrations
below the neutralization endpoint. This is known as anti-
body-dependent enhancement of infection (Morens & Hal-
stead, 1990). NS1 is expressed on the surface of the virus-
infected cells, is secreted into the circulation as a soluble
multimer and is an important target of antibodies against
DV (Young et al., 2000). Antibodies against NS1 can trigger
complement-mediated lysis of DV-infected cells in vitro and
protect mice from DV challenge (Schlesinger et al., 1987). At
the same time, these antibodies may cross-react with endo-
thelial cells, leading to their activation and expression of
cytokine, chemokine and adhesion molecules and resulting
in cell damage (Lin et al., 2005). NS3 protein is the main
antigen that stimulates DV-reactive CD41 and CD81 T cell
cells that produce high levels of interferon (IFN)-g as well as
tumour necrosis factor (TNF)-a, TNF-b, and chemokines
including macrophage inhibitory protein-1b upon interac-
tion with DV-infected antigen presenting cells (APCs), and
are efficient at lysis of DV-infected cells in vitro (Kurane
et al., 1991a; Gagnon et al., 1999; Loke et al., 2001). Shresta
et al. (2004a) reported that IFN-a/b is critical for early
immune responses to DV infection while IFN-g-mediated
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immune responses are crucial for both early and late
clearance of DV infection in mice; thus, the IFN system
plays a more important role than T- and B-cell-dependent
immunity in resistance to primary DV infection in mice. In
another study, Shresta et al. (2004b) concluded that the early
activities of natural killer (NK) cells, B cells and IgM, and
later actions of IFN-g and IgG probably have a role in the
defence against DV infection. Contribution of the immune
responses to the long-term protective immunity by natural
primary DV infection is not fully known.
Pathogenesis of DHF
Despite extensive studies, the pathogenesis of DHF is still
not fully understood. Views have been expressed on the
effect of viral and host factors on disease severity. In Asia,
risk of severe disease is greater in children than in adults,
and outcome is worse in younger children. By contrast,
American strains of DV largely affect the adult population
and produce milder disease. This correlates with the struc-
tural difference in the two strains of DV (Leitmeyer et al.,
1999; Watts et al., 1999; Rico-Hesse, 2003; Cologna et al.,
2005).
Once a virus reaches its target cell, a cascade of events
generally starting with the interaction of viral envelope
glycoproteins with specific entry receptors and co-receptors
is necessary in order to trigger the virus–cell membrane
fusion. DV enters the macrophage (Mf) through a virus
receptor or the Fc-receptor as an immune complex. Schle-
singer & Chapman (1999) have reported that the FcgRI
extracellular domain is sufficient for internalization of
infectious DV immune complexes through a mechanism
that does not involve classical immunoreceptor tyrosine-
based activation motif-dependent signalling. Moreno-Alta-
mirano et al. (2002) have described putative receptors for
DV in primary cultures of human Mf, and Reyes-Del Valle
et al. (2005) have shown that heat shock protein 90 (HSP90)
and HSP70 act as a receptor complex in human cell lines and
in Mf. Furthermore, both HSPs are associated with mem-
brane microdomains in response to DV infection, and
cholesterol-rich membrane fractions are important in DV
entry.
The mechanisms that have been considered in the patho-
genesis of DHF include immune complex disease, anti-
bodies cross-reacting with vascular endothelium, enhancing
antibodies, complement and its products, various soluble
mediators including cytokines, selection of virulent strains
and virus virulence (Halstead, 1993; Chaturvedi et al., 1997,
2000, 2005; Cologna et al., 2005; Lin et al., 2005). DV
actively replicates in B cells and induces them to produce
interleukin (IL)-6 and TNF-a. In addition, a heterologous
antibody is able to enhance both virus and cytokine produc-
tion in B cells. These results suggest that B cells may play an
important role in DV pathogenesis (Lin et al., 2002). The
most significant role in enhancing the severity of the disease
is played by the cascade of cytokines, including a shift from
the predominant helper T-cell type 1 (Th1) response ob-
served in cases of DF to the Th2-type in severe cases of DHF
grade IV (Chaturvedi et al., 1999, 2000, 2005). Patients with
defects in the IL-12 receptor (IL-12R) or IFN-g receptor
(IFN-gR) have abnormal responses to IL-12 or IFN-g and
fail to produce normal levels of IFN-g (Catherinot et al.,
2005; Wood et al., 2005). Current paradigms of T-helper
subset balance predict a high prevalence of DHF in this
group.
Human leucocyte antigen
The human leucocyte antigen (HLA) system is the group of
genes located on chromosome 6 in the human major
histocompatibility complex (MHC) that encodes the cell-
surface antigen-presenting proteins. HLA-A, HLA-B, HLA-
C, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQB1,
HLA-DRA, and HLA-DRB1 are the most thoroughly stu-
died of these genes. HLAs can be further classified into
MHC class I, II and III. Additionally, HLA-DM and HLA-
DO are important in loading the antigenic peptides gener-
ated from pathogens onto the HLA molecules of APCs. The
proteins encoded by HLA are present on the cell surface of
all the nucleated cells and platelets. HLA is used by the cells
of the immune system to differentiate self-and non-self
antigens. Proteins produced inside most cells are displayed
on HLA antigens (specifically class I MHC) on the cell
surface. Infected cells can be recognized and destroyed by
components of the immune system (Cooke & Hill, 2001). A
number of studies have looked at the variation in HLA genes
and found some of them to be associated with severity of DV
infections. Little is known of the role of classical HLA-A and
-B class I alleles in determining resistance, susceptibility or
severity of acute viral infections.
HLA and dengue fever
Increased expression of HLA class I and II molecules on
infected cells has been reported for Flaviviruses, including
DV infection. It is possible that the level of the immune
response generated against virus peptides presented by HLA
molecules may be responsible for the immunopathology of
DV infection (King & Kesson, 2003).
HLA class I
CD81 cytotoxic T lymphocytes (CTLs) play an important in
controlling virus-infected cells. The HLA class I antigens
loaded with viral antigen-derived peptides along with co-
stimulatory receptor/ligand stimuli mediate interactions
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between CD81 T cells and target cells. To escape recognition
and destruction by CD81 T lymphocytes, viruses have
developed strategies to inhibit the expression and/or func-
tion of HLA class I antigens. Thus, HLA class I molecules
restrict CD81 CTL function and mediate immune responses
against ‘endogenous’ antigens and virally infected targets.
HLA class I alleles consist of HLA-A, -B and -C; its products
have a wide distribution and are present on the surface of all
nucleated cells and on platelets.
The data summarized in Table 1 show the HLA alleles
that have been found to be associated with patients with
DF but not in patients with DHF. In some of the studies, the
number of patients was small. In a case-control study of
263 ethnic Thai patients infected with either DV-1, -2, -3 or
-4, an HLA class I association with secondary infections
was detected, but not in patients with primary infections.
HLA-A0203 was associated with the less severe DF, regard-
less of the secondary infecting virus serotype, and HLA-
B52 was associated with DF in patients with secondary
DV-1 and DV-2 infections. Moreover, HLA-B44, -B62, -B76
and -B77 also appear to be protective against developing
clinical disease after secondary DV infection (Stephens
et al., 2002). By contrast, Polizel et al. (2004) reported no
association with any of the 55 HLA class I antigens tested in
patients with DF in a Caucasian Brazilian population. The
lack of a negative association with HLA-I in this study could
be due to differences in ethnicity of the populations or the
different DV serotypes present in the two patient popula-
tions. In this context, it would also be interesting to know
whether susceptibility to either DF or DHF in Brazilians
reveals any differential association with ethnicity, and thus
perhaps with some HLA haplotypes. Note that World
Health Organization definitions do not fit exactly with
patients with DHF in South American countries. Further-
more, dengue mainly affects adults in Brazil but predomi-
nant children in Asia (Phuong et al., 2004; Siqueira et al.,
2005).
HLA class II
HLA class II molecules are involved in the presentation of
‘exogenous’ antigens to T helper cells. Class II HLA products
consist of HLA-D, -DR, -DP and -DQ. They are distributed
on B cells, macrophages, dendritic cells, Langerhan’s cells
and activated T cells. Studies carried out in Mexico on
patients with DV infection showed that HLA-DR4 homo-
zygous individuals are 11.6 times less likely to develop DHF
in comparison with DR4-negative persons These data sug-
gest that in Mexicans, HLA-DR4 may be a genetic factor that
is protective against DHF (LaFleur et al., 2002). Loke et al.
(2001) have studied polymorphisms in the HLA-DRB1 gene
in Vietnamese patients with DHF and did not find any
association. A study of HLA class II specificities for 14 HLA-
DR and four HLA-DQ and DF patients in a Brazilian
population showed a positive association of HLA-DQ1 with
DF and although HLA-DR1 also showed an increased
frequency in the DF group, this was not statistically sig-
nificant (Polizel et al. 2004). Associations with HLA class II
alleles have been shown to play a role in other infections
(Abel & Dessein, 1998; McNicoll, 1998; Thursz, 2001).
HLA and DHF
HLA class I
Polymorphisms in the HLA class I region gene are associated
with DHF disease susceptibility (Table 2). Chiewsilp et al.
(1981) were the first to report an association between HLA
class I and the severity of DV infection. HLA-A and -B typing
on lymphocytes from 87 unrelated Thai children with DSS
and/or DHF was compared with that in 138 controls who
had no clinical dengue infection. A positive association was
seen for HLA-A2 and HLA-B blank and a negative relation-
ship for HLA-B13 (Chiewsilp et al., 1981). Paradoa Perez
et al. (1987) determined the frequency of HLA antigens in 82
Cuban patients with DHF/DSS. The HLA-A1, HLA-B blank,
HLA Cw1 and HLA-A29 antigens showed a significant
difference when their values were compared with the normal
control group. A study of Thai patients with secondary DV
infections showed that HLA-A0207 is associated with
susceptibility to the more severe DHF in patients with
secondary DV-1 and DV-2 infections only. Conversely,
HLA-B51 is associated with the development of DHF in
patients with secondary infections. These results confirm that
classical HLA class I alleles are associated with the clinical
outcome of exposure to DV, in previously exposed and
immunologically primed individuals (Stephens et al., 2002).
HLA class II
T lymphocyte activation during dengue is thought to
contribute to the pathogenesis of DHF. Gagnon et al.
Table 1. Human leucocyte antigen (HLA) alleles associated with protec-
tion against dengue haemorrhagic fever
Class Allele Population Reference
HLA Class I A0203 Thai Stephens et al. (2002)
A29 Cubans Paradoa Perez et al. (1987)
A33 Vietnamese Loke et al. (2001)
B13 Thai Chiewsilp et al. (1981)
B14 Cubans Paradoa Perez et al. (1987)
B44 Thai Stephens et al. (2002)
B52 Thai Stephens et al. (2002)
B62 Thai Stephens et al. (2002)
B76 Thai Stephens et al. (2002)
B77 Thai Stephens et al. (2002)
HLA Class II DRB104 Mexicans LaFleur et al. (2002)
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(2001) examined T-cell receptor Vb gene use by a reverse
transcriptase-PCR assay during infection and after recovery
in 13 children with DHF and 13 children with DF. There was
no deletion of specific Vb gene families. A significant
expansion was detected in use of single Vb families in six
subjects with DHF and three subjects with DF over the
course of infection, but these did not show an association
with clinical diagnosis, viral serotype or HLA alleles. Differ-
ences in Vb gene use between subjects with DHF and
subjects with DF were of borderline significance (Gagnon
et al., 2001). These data suggest that the differences in T-cell
activation in DHF and DF are quantitative rather than
qualitative and that T cells are activated by conventional
antigen(s) and not a viral superantigen.
HLA class III
Genes in the class III region encode a number of proteins,
including complement proteins (C4A, C4B, C2 and Bf),
TNF-a and TNF-b and heat shock proteins (Cooke & Hill,
2001). Loke et al. (2001) studied promotor polymorphisms
in the TNF-a gene but did not find an association with DHF,
and Fernandez-Mestre et al. (2004) studied a single-nucleo-
tide polymorphism and reported a significant increase of the
TNF-308A allele in patients with DHF.
HLA and dengue-primed cells
It is highly likely that DV-reactive T cells may mediate DHF
pathogenesis by cell apoptosis and by inducing secretion of
cytokines that increase vascular permeability (Chaturvedi
et al., 2000, 2005). Analyses of cross-reactivity patterns of
CD41 and CD81 T-cell responses to dengue virus, which is
consistent with the higher level of soluble CD8 in DHF,
points to an important role of T cells in the pathogenesis of
severe dengue disease (Kurane et al., 1991b; Mathew et al.,
1998; Spaulding et al., 1999; Loke et al., 2001).
CD41 T Lymphocyte
CD41 T lymphocytes play a central role in regulating the
cell-mediated immune response to infection. These cells are
also known as ‘helper’ T cells, as they act on other cells of the
immune system to promote various aspects of the immune
response, including immunoglobulin isotype switching and
affinity maturation of the antibody response, macrophage
activation, and enhanced activity of NK cells and CTLs.
Some CD41 T cells can develop into CTLs, but they can
attack only those cell types (e.g. B cells, macrophages,
dendritic cells) that express class II MHCmolecules (Chinen
& Shearer, 2005; Wing et al., 2005).
CD41 T cells recognize antigen that has been processed
and is presented in association with a self-class II MHC
molecule to APCs – B cells, macrophages and dendritic
cells – which take up, process and present the relevant
antigen. The activated CD41 T cell is capable of recognizing
the antigen presented by any cell that expresses the appro-
priate class II MHC molecule. CD41 T cells act by releasing
cytokines in response to antigenic stimulation. The inter-
action between antigen-specific CD41 T cells and macro-
phages forms the basis of the delayed-type hypersensitivity
response, which is one of the main effector mechanisms in
eliminating infections with intracellular organisms (Wing
et al., 2005; Huber & Schramm, 2006).
The role of DV-specific serotype cross-reactive T lym-
phocytes in recovery from and pathogenesis of DV infec-
tions is not fully known. The human CD41 CD8-CTL clone
JK34 cross-reacts for DV types 1, 2, 3 and 4 and recognizes
NS3 (Kurane et al., 1991a). Genotypic typing further
revealed that HLA-DPw2 is the restriction allele for recogni-
tion of an epitope on NS3 by JK34 (Kurane et al., 1993)
(Table 3). The majority of T-cell clones derived from a
donor who received a live experimental DV-3 vaccine cross-
reacts with all four serotypes of DV, but some are serotype
specific or only partially cross-reactive. NS3 is immunodo-
minant in the CD41 T-cell response of this donor. JK15 and
JK13 recognize only DV-3 NS3, JK44 recognizes DV-1, DV-2
and DV-3 NS3, and JK5 recognizes DV-1, DV-3 and West
Nile virus NS3 (Zeng et al., 1996). A study of amino acids
critical for T-cell recognition revealed that clones JK13 and
JK5 recognize the same core epitope that is critical for
recognition by both clones. Sequence analysis of the T-cell
receptors of these two clones showed that they utilize
different VP chains (Zeng et al., 1996). A single epitope can
induce T cells with different virus specificities despite the
restriction of these T cells by the same HLA-DR15 allele.
This suggests complex interactions between human T-cell
receptors and viral epitopes with very similar sequences on
infected cells (Zeng et al., 1996). The clones JK36 and JK46
are cross-reactive for DV-2, 3 and 4, but not for type 1, and
recognize NS3. The smallest synthetic peptide recognized by
Table 2. Human leucocyte antigen alleles associated with susceptibility
to dengue haemorrhagic fever
Class Allele Population References
Class I A1 Cubans Paradoa Perez et al. (1987)
A2 Thai Stephens et al. (2002)
A0207 Thai Stephens et al. (2002)
A24 Vietnamese Loke et al. (2001)
B blank Thai/Cubans Chiewsilp et al. (1981);
Paradoa Perez et al. (1987)
B46 Thai Stephens et al. (2002)
B51 Thai Stephens et al. (2002)
Class II DQ1 Brazil Polizel et al. (2004)
DR1? Brazil Polizel et al. (2004)
Class III TNF-a-308A Venezuela Fernandez-Mestre et al. (2004)
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JK36 has eight amino acids, whereas that by JK46 has 11
(Kurane et al., 1998). Two CD41 CD8-CTL clones, JK4 and
JK43, established from the peripheral blood T lymphocytes
of a DV-4-immune donor cross-reacted with DV-1, 2, 3 and
4, yellow fever virus and West Nile virus, and recognized
NS3. The smallest synthetic peptide recognized by these T
cell clones is an identical nine amino acid peptide of DV-4
NS3. HLA-DR15 is the restriction allele for recognition of
this epitope by JK4 and JK43 clones (Kurane et al., 1995).
Green et al. (1997) examined nine DV-specific human
CD41 CD8-CTL clones for protein recognition, using
recombinant vaccinia viruses that contain genes coding for
DV proteins. These clones were established from peripheral
blood mononuclear cells (PBMCs) of a donor previously
immunized with a live-attenuated experimental DV-1 vac-
cine. Of nine CD41 T-cell clones, seven were DV-1-specific
and two were DV-1, -3 cross-reactive. Four DV-1-specific
clones and one DV-1,-3 cross-reactive clone recognized
epitopes within the NS1 or NS2a proteins. Analysis of HLA
restriction revealed that three DV-1-specific clones are HLA-
DR1-restricted and one DV-1,-3 cross-reactive clone is
HLA-DPw3-restricted (Green et al., 1997). These results
indicate that NS1 and NS2a proteins as well as C, E and
NS3 proteins contain one or more epitopes recognized by
DV-specific human CD41 T lymphocytes.
Okamoto et al. (1998) reported that a region on NS3
contains multiple epitopes recognized by DV serotype-
cross-reactive and flavivirus-cross-reactive CD41 CTLs in
an HLA-DPw2-restricted fashion. Numerous CD41 CTL
lines against DV NS proteins were generated from the bulk
cultures of PBMCs of two patients, KPP94-037 and KPP94-
024, which were specific for NS1 and NS2a collectively and
NS3, respectively. All CTL lines derived from both patients
were cross-reactive with other DV serotypes. The CD41
CTL lines from patient KPP94-037 were HLA DR7 restricted
(Mathew et al., 1998). Mangada & Rothman (2005) mea-
sured the frequencies and characterized the cytokine re-
sponses of DV-specific memory CD41 T cells in PBMCs of
six volunteers who received experimental, live attenuated
monovalent DV vaccines. They demonstrated epitope se-
quence-specific differences in T-cell effector function that
may play a role in the immunopathogenesis of DHF. Thus,
DV-specific CD4 lymphocytes may contribute to immuno-
pathology by lysing virus-infected monocytes, the primary
site of virus replication. Although HLA class I restricted
CD81 CTLs are the major cells responsible for clearing
virus-infected cells, CD41 DV-specific, HLA class II re-
stricted T-cell clones with cytolytic activity have been raised
from individuals infected or vaccinated with DV as cited
above. The HLA-DQ1 and/or DR1 associations may be
explained by their higher efficacy in presenting DV-1
epitopes to CD4 cells.
CD81 T lymphocytes
The CD81 T lymphocytes represent the antigen-specific
CTLs, which respond to and kill cells that are infected with
intracellular pathogens such as viruses. Virtually every cell in
the body expresses class I MHC molecules and can be a
target of CD81 CTLs. In general, the role of the CD81 T
cells is to monitor all the cells of the body, ready to destroy
any that express foreign antigen fragments in their class I
molecules.
Livingston et al. (1995) reported that all four DV-specific
CD81 CD4-CTL clones established from lymphocytes of a
DV-4-immune adult were HLA-B35 restricted and recog-
nized NS3 epitopes. Memory CTL responses of PBMCs
obtained from patients in Thailand 12 months after natural
symptomatic secondary DV infection were studied in four
patients (Mathew et al., 1998). The CD41 and CD81 CTL
lines generated from the bulk cultures of two patients,
KPP94-037 and KPP94-024, which were specific for NS1
and NS2a collectively and NS3 proteins respectively, cross
reacted with other DV serotypes. All CTL lines derived from
both patients were cross-reactive with other DV serotypes.
The CD81 NS1.2a-specific lines from patient KPP94-037
were HLA B57 restricted, and the CD81 NS3-specific lines
from patient KPP94-024 were HLA B7 restricted. A majority
of the CD81 CTLs isolated from patient KPP94-024 were
found to recognize amino acids on NS3 (Mathew et al.,
1998) (Table 4). These results demonstrate that in Thai
patients after symptomatic secondary natural DV infections,
Table 3. Human leucocyte antigen (HLA)-allele restriction of CD41 lymphocytes from dengue immune donors
Source HLA-allele Epitope Specificity Reference
DV-immune patient PBMCs DPw2 NS3 DV-1-2-3-4 cross-reactive Kurane et al. 1991a
DV-immune patient PBMCs DR-15 NS3 Flavivirus cross-reactive Kurane et al. 1995
DV-immune patient PBMCs DR-15 NS3 Flavivirus cross-reactive Zeng et al. 1996
DV vaccine-immunized PBMCs DR1 NS1/NS2a DV-1-specific Green et al. 1997
DV vaccine-immunized PBMCs DPw3 NS1/NS2a DV-1-3 cross-reactive Green et al. 1997
DV-immune patient PBMCs DR-15 NS3 DV-2-3-4 cross-reactive Kurane et al. 1995
DV-immune patient PBMCs DR7 NS11NS2a/NS3 DV-1-2-3-4 cross-reactive Mathew et al. 1998
DV, dengue virus; PBMCs, peripheral blood mononuclear cells.
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CTLs are mainly directed against NS proteins and are
broadly cross-reactive.
In a study of Vietnamese patients with DHF, variation at
the HLA-A locus was significantly associated with suscept-
ibility to DHF, and specific HLA-A susceptibility and
resistance alleles were identified. HLA-A-specific epitopes
were predicted from binding motifs, and ELISPOT analyses
of patients with DHF revealed high frequencies of circulat-
ing CD81 T lymphocytes that recognized both serotype-
specific and -cross-reactive DVepitopes. Thus, strong CD81
T-cell responses are induced by natural DV infection, and
HLA class I genetic variation is a risk factor for DHF (Loke
et al., 2001). Peptides bound by human class I MHC
molecules and presented to CTLs were predicted by a
computer algorithm. The changes in these predicted CTL
epitopes (pCTLE) were restricted by HLA-B()2705 and
were particularly pronounced in DV-1 and DV-3, indicating
CTL-driven selection on DV, particularly, DV-1 and DV-3
(Hughes, 2001).
Zivna et al. (2002) studied the response to an HLA-B07-
restricted T-cell epitope of the DV NS3, in 10 HLA-B07(1)
Thai children during and after acute DV infections. The
frequency of peptide-specific T cells was higher in subjects
who had experienced DHF than in those who had DF. Also
detected were peptide-specific T cells in PBMCs obtained at
the time of the acute DV infection in two of five subjects.
This suggests that the NS3 epitope is an important target of
CD81 T cells in secondary DV infection and that activation
and expansion of DV-specific T cells is greater in subjects
with DHF than in those with DF (Zivna et al., 2002). These
findings support the hypothesis that activation of DV-
specific CD81 T cells plays an important role in the
pathogenesis of DHF. A study of 48 Vietnamese adults with
secondary DV infections suggests that cross-reactive T cells
dominate the acute response during secondary infection.
Acute ELISPOTresponses weakly correlate with the extent of
the disease. NS3 556-564 and Env 414-422 were identified as
novel HLA-A24- and B07-restricted CD81 T-cell epi-
topes, respectively (Simmons et al., 2005). The results high-
light the importance of NS3 and cross-reactive T cells during
acute secondary infection but suggest that the overall
breadth and magnitude of the T-cell response is not sig-
nificantly related to clinical disease grade.
Dendritic cells
DCs are ‘professional’ APCs required for establishing a
primary immune response. Pryor et al. (2001) studied the
association of disease severity with replication of DV isolates
from Asia or America in Mf and also the constructed
recombinant DV with substitutions at residue 390 in the
envelope glycoprotein (E390). The American strain does not
replicate as well as the two Asian strains. For the recombi-
nant viruses, substitution of Asn (Asian) at E390 with Asp
(American) results in decreased ability to replicate in Mf.
This indicates that the lack of association of native American
DV-2 strains with severe disease is linked to reduced ability
to replicate in Mf, and that Asp at E390 may contribute to
this reduction. Using human Mf and DCs, it has been
demonstrated that the chimeric DV containing the E muta-
tion has a lower virus output compared with the parental
infectious clone. A larger reduction in virus output is
observed for the triple mutant and the wild-type, American
genotype virus from which chimeric inserts are derived. It
appears that the three changes function synergistically,
although the E mutation alone gives a lower output com-
pared with the 50- and 30-terminal mutations (Cologna &
Rico-Hesse, 2003).
The DV-infected DCs show maturation markers such as
B7-1, B7-2, HLA-DR, CD11b and CD83, and produce TNF-
a and IFN-a but not IL-6 and IL-12. Although DCs undergo
spontaneous apoptosis in the absence of feeding cytokines,
this process appears to be delayed after DV infection (Ho
et al., 2001). DV-infected DCs induce the interacting T cells
to proliferate and produce IL-2, IL-4, IL-10 and IFN-g (Ho
et al., 2004). Furthermore, preinfection treatment with
either IFN-a or IFN-g effectively arms DCs and limits viral
production in infected cells. However, after infection, DV
develops mechanisms to counteract the protection from
recently added IFN-a, but not IFN-g. Such a selective
antagonism on the antiviral effect of IFN-a, but not IFN-g,
correlates with down-regulated tyrosine-phosphorylation
and DNA-binding activities of STAT1 and STAT3 transcrip-
tion factors by DV (Ho et al., 2005). Shresta et al. (2005)
have demonstrated that IFNR-dependent control of primary
DV infection involves both STAT1-dependent and STAT1-
independent mechanisms. The STAT1 pathway is necessary
Table 4. Human leucocyte antigen (HLA)-allele restriction of CD81 lymphocytes from dengue immune donors
Source HLA-alleles Epitope Specificity Reference
DV-immune patient PBMCs B35 NS3 Cross-reactive Livingston et al. 1995
DV-immune patient PBMCs B7; B57 NS1-NS2a/NS3 Cross-reactive Mathew et al. 1998
Computer prediction B2705 Cross-reactive Hughes 2001
DV-infected or -immune patient PBMCs B07 NS3 Cross-reactive Zivna et al. 2002
DV-immune patient PBMCs A24 and B07 NS3 Cross-reactive Simmons et al. 2005
DV, dengue virus; PBMCs, peripheral blood mononuclear cells.
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for clearing the initial viral load, whereas the STAT1-
independent pathway controls later viral burden and pre-
vents dengue disease in mice. The STAT1-independent
responses in mice with primary DV infection include the
early activation of B and NK cells as well as the up-
regulation of MHC class I molecules on DCs.
DC-specific ICAM-3 grabbing non-integrin (DC-SIGN1,
encoded by CD209), an attachment receptor of DV, is
essential for productive infection of DCs. Sakuntabhai et al.
(2005) have reported a strong association between a pro-
moter variant of CD209, DCSIGN1-336, and risk of DF
compared with DHF or population controls. The G allele
of the variant DCSIGN1-336 is associated with strong
protection against DF in three independent cohorts from
Thailand.
Non-HLA genetic factors
A few studies have investigated the association between
susceptibility to DHF and polymorphic non-HLA alleles,
for example vitamin D receptor (VDR), Fcg receptor II
(FcgRII), IL-4, IL-1 repeat alleles (IL-1RA) and mannose-
binding lectin (MBL) (Table 5). All subclasses of IgG have a
widely distributed Fcg receptor to mediate antibody-depen-
dent enhancement in vitro (van de Winkel and Capel, 1993).
A few infections are associated with an arginine to histidine
substitution at position 131 of the FcgRIIA (Fijen et al.,
1993; Sanders et al., 1994), whereas less susceptiblity to DHF
has been reported with the homozygotes for the arginine
variant at position 131 of the FcgRIIA gene (Loke et al.,
2002).
The immunoregulatory effects of 1.25-dihydroxyvitamin
D3 (1,25D3), including activation of monocytes, stimula-
tion of cellular immune responses, and suppression of
immunoglobulin production and lymphocyte proliferation,
are mediated by the VDR gene (MacDonald et al., 1994).
Recently, the tt genotype of a single nucleotide polymorph-
ism at position 352 of the VDR gene has been reported to be
associated with progression of several infections. Expression
of VDR may affect susceptibility to DHF as activated B and
T lymphocytes express VDR and 1,25D3 affects monocytes,
the main sites of DV infection and replication (Halstead &
O’Rourke, 1977). The t allele at position 352 of the VDR
gene was associated with resistance to severe dengue,
although the exact mechanism needs to be explored (Loke
et al., 2002).
Mannose-binding lectin
Several mutations in the MBL gene have been associated
with several viral infections (Ji et al., 2005; Thio et al., 2005;
Tosi, 2005). Polymorphisms in this gene did not have any
effect on susceptibility to DHF. However, this variant allele
was relatively low in the observed population, which limits
the statistical significance of the data (Loke et al., 2002).
Cytokines
In a number of studies the frequencies of the genotypes
associated with polymorphism of the cytokine genes have
been determined, and their association with the risk of
increasing the severity of various viral infections has been
investigated (Nakayama et al., 2000; Hoebee et al., 2004).
Among the several hypothesis proposed to explain the
pathogenesis of severe dengue disease, the model of cytokine
cascade is the most well supported (Chaturvedi et al., 2000).
The key cytokines that have been associated with DHF
include the shift from Th1-type response in DF to the Th2-
type cytokine response in DHF, with increased levels of IL-
10 and IL-4 (Chaturvedi et al., 1999). The increased levels of
TNF-a (reviewed by Chaturvedi et al., 2000), tumour
growth factor (TGF)-b (Agarwal et al., 1999b) and IL-8
(Raghupathy et al., 1998) have been associated with DHF,
and that of IL-12 with DF (Pacsa et al., 2000). Polymor-
phism of the genes of these cytokines have been shown in a
number of diseases, including viral infections, but little
effort has been made to study cytokine polymorphism in
patients with DV infection. Loke et al. (2002) have studied
IL-4 promotor and IL-1 repeat allele polymorphisms but
found no relationship with susceptibility to DHF. By con-
trast, Fernandez-Mestre et al. (2004) have studied a single-
nucleotide polymorphism of TNF-a, IFN-g, IL-6, TGF-b1
and IL-10 in patients with DV infections and reported a signi-
ficant increase of the TNF-308A allele in patients with DHF.
Conclusions
Differences in susceptibility to disease can be seen at the
level of individuals and populations. Genetic epidemiology
data indicate that there might be major susceptibility genes
that account for a significant proportion of the genetic
contribution to disease susceptibility. Several single-gene
disorders have been implicated in altered susceptibility to
many different infectious diseases. HLA loci evolve very
rapidly, probably as a result of selective pressure from
pathogens, and polymorphisms in these loci have been
associated with altered susceptibility to infectious diseases.
Table 5. Effects of non-human leucocyte antigen alleles on the severity
of dengue virus infections
Allele Effects Population Reference
Fc gamma-receptor Resistance Vietnamese Loke et al. 2002
Vitamin D receptor Resistance Vietnamese Loke et al. 2002
Mannose-binding lectin No effect Vietnamese Loke et al. 2002
DCSIGN1-336 Resistance France Sakuntabhai et al.
2005
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Several non-HLA genes have also been linked with increased
susceptibility to disease, e.g. TNF-a, VDR, and perhaps
other cytokine genes. The findings of several recent studies
of the genetic influence on IL-12 and IFN-g receptor
functions in various diseases indicate a need for such studies
with regard to DV infection. Our knowledge of the mole-
cular mechanisms used by viruses to inhibit the expression
of HLA class I antigen/peptide complexes on the cell surface
is not only crucial to understanding the pathogenesis of viral
diseases, but may also contribute to the design of new
strategies to inhibit the escape mechanisms used by viruses.
These studies may lead to the development of effective
immunotherapies to control viral infections. The scant
positive data presented here indicate a need for detailed
genetic studies in different ethnic groups in different coun-
tries during the acute phase of DF and DHF on a larger
number of patients.
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